Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities

Translational Lung Cancer Research

Volumn 4, Issue 5, 2015, Pages 560-575

  Villadolid, Jeryl ^a   Amin, Asim ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Checkpoint inhibition; Immunotherapy; Toxicity

Indexed keywords

EID: 84958181736     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.06.06     Document Type: Review

References (20)

1. Yervoy® [package insert]. Princeton, NJ, USA: Bristol-Myers Squibb Company, 2013. Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66, accessed June 2015.
2. Keytruda® [package insert]. Whitehouse Station, NJ, USA: Merck & Co., Inc., 2015. Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287, accessed June 2015.
3. Opdivo® [package insert]. Princeton, NJ, USA: Bristol-Myers Squibb Company, 2015. Available online: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394, accessed June 2015.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
6. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17.
7. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
8. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
9. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.
10. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
12. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
13. YERVOY™ (ipilimumab) US Prescribing Information: Risk Evaluation and Mitigation Strategy (REMS). Princeton, NJ, USA: Bristol-Myers Squibb Company, 2011. Available online: https://www.hcp.yervoy.com/pages/rems.aspx, accessed April 2015.
14. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
15. Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013;18:733-43.
16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines) Melanoma. Version 3. 2015. Available online: www.nccn.org, accessed April 2015.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available online: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf, accessed April 2015.
18. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
19. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
20. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014;312:1744-53.